Ikarian Capital’s Cidara Therapeutics CDTX Stock Holding History

Ikarian Capital’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-273,243	Closed	-$60.4M	–	172
2025 Q4	$60.4M	Sell	273,243 -4,461	-2%	-$721K	4.71%	5
2025 Q3	$26.6M	Sell	277,704 -186,784	-40%	-$11.9M	2.69%	8
2025 Q2	$22.6M	Buy	464,488 +215,548	+87%	+$5.18M	4.35%	2
2025 Q1	$5.36M	Buy	248,940 +195,000	+362%	+$4.33M	0.66%	33
2024 Q4	$1.45M	Buy	+53,940	New	+$876K	0.2%	94

Ikarian Capital's CDTX Position: Q1 2026 in Review

Ikarian Capital sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 273,243 shares — an estimated $60.4M sold.

Ikarian Capital first reported a position in CDTX in Q4 2024 and held it in 5 quarters. The position peaked at $60.4M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

Ikarian Capital reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
Ikarian Capital sold 273,243 Cidara Therapeutics shares in Q1 2026, an estimated $60.4M.
Ikarian Capital first reported a position in Cidara Therapeutics in Q4 2024 and held it in 5 quarters.
Ikarian Capital's Cidara Therapeutics position peaked at $60.4M in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.